Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease.
作者信息
Schell Trevor L, Knutson Keith L, Saha Sumona, Wald Arnold, Phan Hiep S, Almasry Mazen, Chun Kelly, Grimes Ian, Lutz Megan, Hayney Mary S, Farraye Francis A, Caldera Freddy
机构信息
Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
Department of Immunology, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
出版信息
Inflamm Bowel Dis. 2022 Nov 2;28(11):1781-1786. doi: 10.1093/ibd/izac082.
Abstract
摘要
相似文献
1
Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease.3剂新型冠状病毒肺炎信使核糖核酸疫苗在炎症性肠病患者中的体液免疫原性
Inflamm Bowel Dis. 2022 Nov 2;28(11):1781-1786. doi: 10.1093/ibd/izac082.
2
Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination.COVID-19 疫苗接种后，接受抗 TNF 治疗的炎症性肠病患者的细胞介导免疫反应更高。
Inflamm Bowel Dis. 2023 Aug 1;29(8):1202-1209. doi: 10.1093/ibd/izac193.
3
Persistence of Antibodies Six Months after Three COVID-19 mRNA Vaccine Doses in Patients with Inflammatory Bowel Disease.炎症性肠病患者接种三剂新冠病毒mRNA疫苗六个月后抗体的持久性
Inflamm Bowel Dis. 2023 Oct 3;29(10):1662-1666. doi: 10.1093/ibd/izad019.
4
INTERACTIONS AMONG INTERLEUKIN-6, C-REACTIVE PROTEIN AND INTERLEUKIN-6 (-174) G/C POLYMORPHISM IN THE PATHOGENESIS OF CROHN'S DISEASE AND ULCERATIVE COLITIS.白细胞介素-6、C反应蛋白与白细胞介素-6（-174）G/C多态性在克罗恩病和溃疡性结肠炎发病机制中的相互作用
Acta Clin Croat. 2020 Mar;59(1):67-80. doi: 10.20471/acc.2020.59.01.09.
5
BNT162b2 mRNA COVID-19 vaccine is safe in a setting of patients on biologic therapy with inflammatory bowel diseases: a monocentric real-life study.BNT162b2 mRNA COVID-19 疫苗在接受生物治疗的炎症性肠病患者中是安全的：一项单中心真实世界研究。
Expert Rev Clin Pharmacol. 2022 Oct;15(10):1243-1252. doi: 10.1080/17512433.2022.2120466. Epub 2022 Sep 8.
6
[A surgically relevant summary of the addendum to the S3 guidelines of the DGVS on Crohn's disease and ulcerative colitis : Treatment of chronic inflammatory bowel diseases in the COVID-19 pandemic].[德国胃肠病学、消化和代谢疾病学会（DGVS）关于克罗恩病和溃疡性结肠炎的S3指南附录的外科相关总结：2019冠状病毒病大流行期间慢性炎症性肠病的治疗]
Chirurg. 2021 Jan;92(1):30-33. doi: 10.1007/s00104-020-01321-5.
7
Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease.主要组织相容性复合体基因在炎症性肠病易感性及疾病表型中的作用
Lancet. 1996 May 4;347(9010):1212-7. doi: 10.1016/s0140-6736(96)90734-5.
8
Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy.标准剂量和第三剂 SARS-CoV-2 疫苗接种在接受免疫抑制治疗患者中的免疫原性和安全性。
Arthritis Rheumatol. 2022 Aug;74(8):1321-1332. doi: 10.1002/art.42153. Epub 2022 Jun 29.
9
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.SARS-CoV-2 疫苗接种对炎症性肠病活动和疫苗相关不良事件发展的影响：来自 PREVENT-COVID 的结果。
Inflamm Bowel Dis. 2022 Oct 3;28(10):1497-1505. doi: 10.1093/ibd/izab302.
10
Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta-analysis.炎症性肠病患者感染冠状病毒病的风险和结局：系统评价和荟萃分析。
United European Gastroenterol J. 2021 Mar;9(2):159-176. doi: 10.1177/2050640620972602. Epub 2021 Mar 23.
引用本文的文献
1
A Practical Update on COVID-19 and Inflammatory Bowel Disease: COVID-19 Disease Risk and Vaccine Safety and Efficacy.新型冠状病毒肺炎与炎症性肠病实用最新进展：新型冠状病毒肺炎疾病风险及疫苗安全性与有效性
Gastroenterol Hepatol (N Y). 2024 Feb;20(2):88-97.
2
Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy.接受抗肿瘤坏死因子治疗的炎症性肠病患者接种3剂mRNA新冠疫苗后产生更高且持续的细胞介导免疫反应。
Clin Transl Gastroenterol. 2024 Apr 1;15(4):e00688. doi: 10.14309/ctg.0000000000000688.
3
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects.免疫抑制的炎症性肠病患者第三次接种严重急性呼吸综合征冠状病毒2疫苗后的体液免疫：与健康对照者的比较
Vaccines (Basel). 2023 Aug 24;11(9):1411. doi: 10.3390/vaccines11091411.
4
Antibody Kinetics after Three Doses of SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease.炎症性肠病患者接种三剂 SARS-CoV-2 mRNA 疫苗后的抗体动力学。
Medicina (Kaunas). 2023 Aug 18;59(8):1487. doi: 10.3390/medicina59081487.
5
COVID-19 vaccination in adults with inflammatory bowel disease.炎症性肠病成年患者的新冠病毒疫苗接种
Therap Adv Gastroenterol. 2023 May 22;16:17562848231173130. doi: 10.1177/17562848231173130. eCollection 2023.
6
COVID-19 Vaccination Among Individuals With Inflammatory Bowel Disease: Perception, Efficacy, and Safety.炎症性肠病患者的新冠病毒疫苗接种：认知、疗效与安全性
Gastroenterol Hepatol (N Y). 2022 Jul;18(7):388-399.
7
Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.肠道炎症中 SARS-CoV-2 免疫的全身和 T 细胞相关反应（STAR SIGN 研究）：生物制剂对 mRNA 疫苗第三剂预防 SARS-CoV-2 效果的影响。
Aliment Pharmacol Ther. 2023 Jan;57(1):103-116. doi: 10.1111/apt.17264. Epub 2022 Oct 28.
8
Impact of Anti-TNFα Treatment on the Humoral Response to the BNT162b2 mRNA COVID-19 Vaccine in Pediatric Inflammatory Bowel Disease Patients.抗TNFα治疗对儿童炎症性肠病患者针对BNT162b2 mRNA新冠疫苗的体液免疫反应的影响
Vaccines (Basel). 2022 Sep 27;10(10):1618. doi: 10.3390/vaccines10101618.
9
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.COVID-19 疫苗接种后第三剂后炎症性肠病免疫抑制患者的抗体和 T 细胞反应（VIP）：一项多中心、前瞻性、病例对照研究。
Lancet Gastroenterol Hepatol. 2022 Nov;7(11):1005-1015. doi: 10.1016/S2468-1253(22)00274-6. Epub 2022 Sep 9.
10
Booster COVID-19 Vaccines for Immune-Mediated Inflammatory Disease Patients: A Systematic Review and Meta-Analysis of Efficacy and Safety.免疫介导性炎症疾病患者的新冠病毒加强疫苗：疗效与安全性的系统评价和荟萃分析
Vaccines (Basel). 2022 Apr 22;10(5):668. doi: 10.3390/vaccines10050668.
Zotero 插件